BAJAJ BROKING
The U.S. FDA classified Biocon Biologics’ Johor Bahru insulin facilities as Voluntary Action Indicated (VAI) after inspecting multiple biologics manufacturing and quality control units in September 2024.
Biocon Biologics’ insulin manufacturing facilities in Johor Bahru, Malaysia, have been classified as Voluntary Action Indicated (VAI) by the U.S. Food and Drug Administration (FDA). The classification follows a comprehensive cGMP inspection conducted between 15 and 27 September 2024. The inspection covered multiple biologics manufacturing units, including a Drug Substance unit, Drug Product unit, Medical Device Assembly unit, Analytical Quality Control Laboratory, two Microbiological Control Laboratories, and two Warehouses.
Also read: JSW Energy Completes ₹630 Crore Acquisition of 125 MW RE Assets
FDA conducted a cGMP inspection of Biocon Biologics facilities in September 2024.
Inspection scope included eight manufacturing and quality control units.
Facilities classified as Voluntary Action Indicated (VAI).
Also read: DMart Appoints Anshul Asawa as CEO Designate, Succeeding Ignatius Noronha
The FDA’s inspection included a thorough evaluation of Biocon Biologics’ key manufacturing and quality control facilities.
Unit Inspected | Function |
Drug Substance Unit | Produces active ingredients for insulin |
Drug Product Unit | Manufactures final insulin formulations |
Medical Device Assembly Unit | Assembles insulin delivery devices |
Analytical Quality Control Laboratory | Ensures product quality and compliance |
Microbiological Control Laboratories | Conduct microbiological testing |
Warehouses | Store raw materials and finished products |
The VAI classification indicates that while certain observations were made, no critical violations requiring mandatory action were identified. This recognition further solidifies Biocon Biologics’ commitment to maintaining global quality and compliance standards.
The FDA’s VAI classification for Biocon Biologics’ Johor Bahru facilities reflects the company’s consistent adherence to cGMP guidelines. This development may positively influence the Biocon Biologics share price as the company continues its focus on quality manufacturing for global markets.
Also read: Interarch Secures ₹221 Crore Projects in Semiconductors & Energy Storage
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading